14-day Premium Trial Subscription Try For FreeTry Free
$0.0200
-0.0090 (-31.03%)
At Close: Apr 24, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.0200 $0.0500 Wednesday, 24th Apr 2024 CALA stock ended at $0.0200. This is 31.03% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 0% from a day low at $0.0200 to a day high of $0.0200.
90 days $0.0200 $0.120
52 weeks $0.0100 $0.500

Historical Calithera Biosciences prices

Date Open High Low Close Volume
Feb 12, 2024 $0.0305 $0.0305 $0.0305 $0.0305 19 334
Feb 09, 2024 $0.0301 $0.0301 $0.0301 $0.0301 255
Feb 08, 2024 $0.0300 $0.0300 $0.0300 $0.0300 3 799
Feb 07, 2024 $0.0300 $0.0305 $0.0300 $0.0300 2 736
Feb 06, 2024 $0.0332 $0.0332 $0.0300 $0.0325 1 324
Feb 05, 2024 $0.0313 $0.0313 $0.0313 $0.0313 0
Feb 02, 2024 $0.0313 $0.0313 $0.0313 $0.0313 310
Feb 01, 2024 $0.0300 $0.0313 $0.0300 $0.0313 868
Jan 31, 2024 $0.0300 $0.0300 $0.0300 $0.0300 201
Jan 30, 2024 $0.0308 $0.0308 $0.0300 $0.0300 1 215
Jan 29, 2024 $0.0300 $0.0300 $0.0300 $0.0300 3 982
Jan 26, 2024 $0.0300 $0.0300 $0.0300 $0.0300 0
Jan 25, 2024 $0.0300 $0.0300 $0.0300 $0.0300 920
Jan 24, 2024 $0.0300 $0.0300 $0.0300 $0.0300 179
Jan 23, 2024 $0.0300 $0.0300 $0.0300 $0.0300 1 015
Jan 22, 2024 $0.0300 $0.0313 $0.0300 $0.0313 432
Jan 19, 2024 $0.0313 $0.0313 $0.0313 $0.0313 0
Jan 18, 2024 $0.0313 $0.0313 $0.0313 $0.0313 154
Jan 17, 2024 $0.0300 $0.0500 $0.0300 $0.0300 7 172
Jan 16, 2024 $0.0313 $0.0313 $0.0313 $0.0313 100
Jan 12, 2024 $0.0300 $0.0300 $0.0300 $0.0300 1 011
Jan 11, 2024 $0.0300 $0.0300 $0.0300 $0.0300 0
Jan 10, 2024 $0.0300 $0.0300 $0.0300 $0.0300 107
Jan 09, 2024 $0.0313 $0.0313 $0.0313 $0.0313 0
Jan 08, 2024 $0.0313 $0.0313 $0.0313 $0.0313 0
Click to get the best stock tips daily for free!

About Calithera Biosciences

Calithera Biosciences Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginas... CALA Profile

Golden Star

Ticker Date Change Price
MLI Apr 19 10.86% $52.28
LPLA Apr 19 0.743% $262.59
DOOR Apr 18 0.160% $131.39
LNG Apr 17 0.389% $156.81
FCN Apr 16 2.95% $207.62
ELV Apr 16 5.28% $506.97
DXC Apr 08 0.767% $20.87
AKR Apr 05 5.63% $16.53
ITCI Apr 05 6.84% $68.44
SARK Mar 28 13.80% $26.88
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT